At SARKKOS Therapeutics, we are driven by our mission to bridge the gap between metabolic dysfunction and oncology with scientifically validated mechanism-based targeted therapies for the benefit of obese patients suffering from solid cancer. We aim to develop innovative, small-molecule targeted anti-tumour therapies that address the unique biological challenges of obesity-related solid cancers, improving survival and quality of life for underserved patient populations.